These findings support that chemotherapy-activated TGF-β signaling promotes tumor relapse by expanding CSCs in an IL-8-contingent mechanism, and TGF-β pathway inhibitors could potentially circumvent the acquisition of drug-resistant CSCs. Here, TGFB1 is linked to neoplasm.